Homocysteine, malondialdehyde and endothelial markers in dialysis patients during low-dose folinic acid therapy

Journal of Internal Medicine

Volumn 252, Issue 5, 2002, Pages 456-464

  Apeland, Terje ^a   Mansoor, M A ^a   Seljeflot, I ^b   Bronstad I ^a   Goransson L ^a   Strandjord, R E ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Endothelial activation; Folate; Folinic acid; Haemodialysis; Homocysteine; Lipid peroxidation

Indexed keywords

AFI B TOTAL FORTE; AMINO ACID; ANTILIPEMIC AGENT; BIOCHEMICAL MARKER; CELL ADHESION MOLECULE; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; FOLINIC ACID; HEMOSTATIC AGENT; HOMOCYSTEINE; MALONALDEHYDE; NICOTINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; THROMBOMODULIN; VITAMIN B GROUP; CREATININE; HEMOGLOBIN; SERUM ALBUMIN;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; ARTIFICIAL KIDNEY; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CLINICAL ARTICLE; ENDOTHELIUM CELL; FEMALE; FOLIC ACID BLOOD LEVEL; HEMODIALYSIS; HEMOSTASIS; HUMAN; LIPID PEROXIDATION; LONGITUDINAL STUDY; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; OUTCOMES RESEARCH; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; UREMIA; VITAMIN SUPPLEMENTATION; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; MUTATION; RENAL REPLACEMENT THERAPY; VASCULAR ENDOTHELIUM;

CREATININE; ENDOTHELIUM, VASCULAR; FEMALE; HEMOGLOBINS; HOMOCYSTEINE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; LEUCOVORIN; LONGITUDINAL STUDIES; MALE; MALONDIALDEHYDE; MIDDLE AGED; MUTATION; RENAL DIALYSIS; SERUM ALBUMIN;

EID: 0036879305     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2002.01056.x     Document Type: Article

References (40)

1. Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 1999; 10: 891-900.
2. Raine AE, Margreiter R, Brunner FP et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992; 7 (Suppl. 2): 7-35.
3. Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997; 8: 475-86.
4. Bostom AG, Shemin D, Verhoef P et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 1997; 17: 2554-8.
5. Moustapha A, Naso A, Nahlawi M et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97: 138-41.
6. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-50.
7. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements, metaanalysis of randomised trials. BMJ 1998; 316: 894-8.
8. Suliman ME, Divino Filho JC, Barany P, Anderstam B, Lindholm B, Bergstrom J. Effects of high-dose folic acid and pyridoxine on plasma and erythrocyte sulfur amino acids in hemodialysis patients. J Am Soc Nephrol 1999; 10: 1287-96.
9. Bostom AG, Shemin D, Lapane KL et al. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49: 147-52.
10. Arnadottir M, Brattstrom L, Simonsen O et al. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993; 40: 236-40.
11. Massy ZA. Reversal of hyperhomocyst(e)inaemia in chronic renal failure-is folic or folinic acid the answer? Nephrol Dial Transplant 1999; 14: 2810-2.
12. Touam M, Zingraff J, Jungers P, Chadefaux-Vekemans B, Drueke T, Massy ZA. Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int 1999; 56: 2292-6.
13. van Guldener C, Kulik W, Berger R et al. Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidney Int 1999; 56: 1064-71.
14. Yango A, Shemin D, Hsu N et al. Rapid communication. L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Kidney Int 2001; 59: 324-7.
15. Hauser AC, Hagen W, Rehak PH et al. Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients. Am J Kidney Dis 2001; 37: 758-65.
16. Stenvinkel P, Lindholm B, Heimburger M, Heimburger O. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 2000; 15: 1624-30.
17. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 1990; 9: 515-40.
18. Mansoor MA, Svardal AM, Schneede J, Ueland PM. Dynamic relation between reduced, oxidized, and protein-bound homocysteine and other thiol components in plasma during methionine loading in healthy men. Clin Chem 1992; 38: 1316-21.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
20. Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress, reference interval and effects of life-style factors. Clin Chem 1997; 43: 1209-14.
21. Gudnason V, Stansbie D, Scott J, Bowron A, Nicaud V, Humphries S. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR). its frequency and impact on plasma homocysteine concentration in different European populations. EARS group. Atherosclerosis 1998; 136: 347-54.
22. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase [letter]. Nat Genet 1995; 10: 111-3.
23. Schalhorn A, Kuhl M. Clinical pharmacokinetics of fluorouracil and folinic acid. Semin Oncol 1992; 19 (Suppl. 3): 82-92.
24. Campbell NR. How safe are folic acid supplements? Arch Intern Med 1996; 156: 1638-44.
25. Kelly P, McPartlin J, Goggins M, Weir DG, Scott JM. Unmetabolized folic acid in serum, acute studies in subjects consuming fortified food and supplements. Am J Clin Nutr 1997; 65: 1790-5.
26. Fodinger M, Mannhalter C, Wolfl G et al. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997; 52: 517-23.
27. Bostom AG, Shemin D, Lapane KL et al. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 1996; 123: 193-202.
28. Hustad S, Ueland PM, Vollset SE, Zhang Y, Bjorke-Monsen AL, Schneede J. Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin Chem 2000; 46 (8 Part 1): 1065-71.
29. Kunz K, Petitjean P, Lisri M et al. Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link? Nephrol Dial Transplant 1999; 14: 1934-42.
30. Borawski J, Naumnik B, Pawlak K, Mysliwiec M. Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response. Nephrol Dial Transplant 2001; 16: 1442-7.
31. Mezzano D, Pais EO, Aranda E et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001; 60: 1844-50.
32. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92.
33. Semaan HB, Gurbel PA, Anderson JL et al. Soluble VCAM-1 and E-selectin, but not ICAM-1 discriminate endothelial injury in patients with documented coronary artery disease. Cardiology 2000; 93: 7-10.
34. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-14.
35. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation 2000; 102: 871-5.
36. van Guldener C, Janssen MJ, Lambert J, ter Wee PM, Donker AJ, Stehouwer CD. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy. Perit Dial Int 1998; 18: 282-9.
37. Chambers JC, Ueland PM, Obeid OA, Wrigley J, Refsum H, Kooner JS. Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000; 102: 2479-83.
38. Healy H, Reith D, Morgan C, Clague A, Westhuyzen J. Are metalloproteins and acute phase reactants associated with cardiovascular disease in end-stage renal failure? Ann Clin Laboratory Sci 2000; 30: 295-304.
39. Boaz M, Matas Z, Biro A et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 1999; 56: 1078-83.
40. Bayes B, Pastor MC, Bonal J, Junca J, Romero R. Homocysteine and lipid peroxidation in haemodialysis: role of folinic acid and vitamin E. Nephrol Dial Transplant 2001; 16: 2172-5.